Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO4929097 monotherapy in recurrent or refractory non-small cell lung cancer
2008-006384-37Phase 2Terminated
- Sponsor
- Roche
- Start
- Jul 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of RO4929097 in non-small cell lung cancer (NSCLC), sponsored by Roche. Primary endpoints: Change in tumor blood flow, Tumor metabolic response rate and 1 more. Started Jul 2009; status: terminated.
02
Drugs
RO4929097
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2008-006384-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006384-37.